gefitinib has been researched along with bicalutamide in 9 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (bicalutamide) | Trials (bicalutamide) | Recent Studies (post-2010) (bicalutamide) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 1,313 | 212 | 541 |
Protein | Taxonomy | gefitinib (IC50) | bicalutamide (IC50) |
---|---|---|---|
Progesterone receptor | Oryctolagus cuniculus (rabbit) | 5.6 | |
Progesterone receptor | Homo sapiens (human) | 1.819 | |
Androgen receptor | Homo sapiens (human) | 0.404 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.7168 | |
Androgen receptor | Mus musculus (house mouse) | 1.835 | |
Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | 0.12 | |
Progesterone receptor | Rattus norvegicus (Norway rat) | 0.89 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C | 1 |
1 review(s) available for gefitinib and bicalutamide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for gefitinib and bicalutamide
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds | 2007 |